Matulonis, U. A., Oza, A. M., Secord, A. A., Roman, L. D., Blagden, S. P., Banerjee, S. N., … Matei, D. (2016). Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. In Journal of Clinical Oncology (Vol. 34, pp. 5547–5547). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.5547

Matulonis, Ursula A., Amit M. Oza, Angeles Alvarez Secord, Lynda D. Roman, Sarah Patricia Blagden, Susana N. Banerjee, J. C. Elkas, et al. “Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.” In Journal of Clinical Oncology, 34:5547–5547. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5547.

Matulonis UA, Oza AM, Secord AA, Roman LD, Blagden SP, Banerjee SN, et al. Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5547–5547.

Matulonis, Ursula A., et al. “Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 5547–5547. Crossref, doi:10.1200/jco.2016.34.15_suppl.5547.

Matulonis UA, Oza AM, Secord AA, Roman LD, Blagden SP, Banerjee SN, Elkas JC, Nemunaitis JJ, Ghamande SA, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit RS, Naim S, Hao Y, Keer HN, Azab M, Matei D. Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5547–5547.